Background: Tartrate-resistant acid phosphatase 5 (ACP5) is an evolutionarily conserved and multifunctional
protein that is involved in generations of reactive oxygen species, normal bone development, osteoblast
regulation and macrophage function, affecting a series of pathways, as well as reflecting bone resorption
and osteoclast activity.
Methods: Literature searches, systematic reviews and assessments about the structure, distribution, regulation
and novel functions of ACP5 were performed in this review from PubMed and Medline databases.
Results: Studies demonstrate that RANKL can increase the expression of ACP5 through NFATc1 and c-Fos to
accelerate osteoclastogenesis, which also can be regulated by many regulators. Based on the aforementioned
information, it is shown that ACP5, together with the phosphatase activity, can medicate the progression and
development of human genetic diseases and cancer.
Conclusion: As a novel target, ACP5 plays a critical role in preventing, monitoring and treating various kinds of
tumors, as well as accelerating the development of a promising therapeutic strategy for human genetic diseases.
However, the explicit mechanism between ACP5 and cancer is not so clear. It is necessary and significant for us
to pay more in-depth attention.